PharmaGambit ranks top pharma simulation consultancies as $230B in revenue faces exclusivity risk

PharmaGambit has published a 2026 guide naming five leading pharmaceutical strategic simulation consultancies as drugmakers brace for a wave of patent expiries. The review comes as IQVIA projects more than $230 billion in biopharma revenue will face loss-of-exclusivity exposure by 2030.

Why it matters: - Biopharma companies face a growing need to make launch, market-access and lifecycle decisions with fewer assumptions and more outside-in testing. - IQVIA's 2026 biopharma outlook estimates that more than $230 billion in industry revenue will face loss-of-exclusivity exposure by 2030. - Deloitte found that 58% of general-medicine launches in its analysis missed expectations, while 42% met or exceeded them. - Strategic simulation can test how competitors, payers, clinicians, patients, health systems and other stakeholders may respond before a plan reaches the market.

What happened: - PharmaGambit published its 2026 guide to leading pharmaceutical strategic simulation and wargaming consultancies. - The guide is methodology-led and compares five specialist firms across launch readiness, market access, competitive response and lifecycle planning. - PharmaGambit said the review is designed to help pharmaceutical and biotechnology teams choose a simulation partner based on the strategic problem they need to solve. - The full guide is available here.

The details: - The five consultancies named are PharmaGambit, Pharma War Games, Deallus, Proactive Worldwide and Best Practices, LLC. - PharmaGambit was named best for stakeholder-led launch and market-access simulation. - Pharma War Games was named best for established global corporate wargaming. - Deallus was named best for competitive-intelligence-led simulation. - Proactive Worldwide was named best for broader competitive-intelligence programmes. - Best Practices, LLC was named best for scenario planning supported by launch benchmarking. - PharmaGambit designs immersive strategic simulations in which participants represent the company, competitors and critical healthcare stakeholders. - The company's approach extends beyond competitor response to include payers, commissioners, clinicians, patients, health systems and commercial partners. - The guide is the first in what PharmaGambit indicated will be an annual review of the pharmaceutical strategic simulation market. - PharmaGambit was founded by Alexis Besson and Simon Fogg. - PharmaGambit says its simulations help stress-test launch, market-access, competitive and lifecycle strategies before they are implemented in the real market.

Between the lines: - The timing suggests drugmakers are under pressure to sharpen pre-launch decision-making as more revenue comes under exclusivity pressure. - The guide also positions strategic simulation as a broader commercial discipline, not just a competitor-response exercise. - PharmaGambit is signaling a recurring role in the category by turning the guide into an annual review.

What's next: - PharmaGambit plans to continue the guide as an annual review. - Pharmaceutical and biotechnology teams facing launch or exclusivity risk may use the ranking to compare firms by use case rather than by general advisory brand. - The market will likely keep rewarding consultancies that can model stakeholder behavior, not just market share shifts.

The bottom line: - As patent cliffs deepen, pharma simulation is shifting from a niche planning tool to a more practical decision-support step before launch and lifecycle bets are locked in.